Sponsor Pipeline

Essen Biotech Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
17
Active Trials
17
Recruiting
10
Disease Areas
Active Trials by Phase
Phase 1/2
17
Active Trials
NCT IDTitleConditionStatus
Phase 1/2
NCT06350110 Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus… Systemic Lupus Erythematosus Recruiting
NCT06538012 TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer Lung Cancer Recruiting
NCT06399107 Investigation Into the Use of BAH243 Lentiviral Vector for Gene Therapy in Treating… Sickle Cell Disease Recruiting
NCT06428188 Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory… Autoimmune Diseases Recruiting
NCT06530303 Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum… Colorectal Cancer Recruiting
NCT06640582 TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and… Brain Tumor Recruiting
NCT06420063 Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML AML Recruiting
NCT06420076 Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia… T Cell Lymphoma Recruiting
NCT06532799 TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and… Stomach Cancer Recruiting
NCT06532812 TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast… Breast Cancer Recruiting
NCT07032129 Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory… Multiple Myeloma Recruiting
NCT07066982 Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With… Sarcoma Recruiting
NCT07066995 Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer Pancreatic Cancer Recruiting
NCT07067255 Sequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer Ovarian Cancer Recruiting
NCT06213636 Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia… Acute Lymphoblastic Leukemia, Adult B-Cell Recruiting
NCT07410494 Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced… Cancer Recruiting
NCT07410676 EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors Cancer Recruiting
Disease Areas
Get alerts when Essen Biotech's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free